Skip to main content

Advertisement

Log in

Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The clinical outcome for elderly patients with diffuse large B-cell lymphoma (DLBCL) has improved. However, the management of elderly patients with cancer is frequently complicated by their coexisting disorders. The aim of this study was to evaluate the correlation between comorbid medical status and clinical outcome among elderly patients with DLBCL.

Methods

We retrospectively analyzed all patients over 65 years old with newly diagnosed DLBCL from 2001 to 2008 in our institution. To assess their comorbid medical status, we calculated Charlson Comorbidity Index (CCI) of each patient without considering primary disease and then divided them into low CCI (0 or 1) or high CCI group (2 or more).

Results

A total of 80 patients from age of 66–90 years (median 73 years) were analyzed. Seventy-two patients (90%) were treated with cyclophosphamide-, doxorubicin-, vincristine-, and prednisone (CHOP)-based chemotherapy, and 14 patients (18%) were assigned to high CCI. The overall survival (OS) rate at 3 years for all patients was 70%, with significant difference between good and poor risk patients in revised International Prognostic Index (IPI) (90 vs. 45%, P < 0.0001). Multivariate analysis revealed high CCI was associated with worse OS, while independent of other prognostic factors consisting IPI (hazard ratio 4.44, 95% confidence interval [1.63–11.3], P = 0.0045). In addition, high CCI group was significantly inferior to low CCI group for overall response rate (93 vs. 64% P = 0.0158) and 3-year OS (85 vs. 55% P = 0.0026), respectively.

Conclusions

Among elderly DLBCL, high CCI was independently associated with worse outcome. Novel discrete strategies for these deteriorated patients are therefore warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  • Balducci L, Extermann M (2000) Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 14(1):1–16

    Article  PubMed  CAS  Google Scholar 

  • Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

    Article  PubMed  CAS  Google Scholar 

  • Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795

    Article  PubMed  CAS  Google Scholar 

  • Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y (1988) Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24(9–10):533–538

    PubMed  CAS  Google Scholar 

  • Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126. doi:10.1200/JCO.2005.09.131

    Article  PubMed  CAS  Google Scholar 

  • Gridelli C (2008) Treatment of advanced non small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. J Clin Oncol 26(1):13–15. doi:10.1200/JCO.2007.14.1820

    Article  PubMed  Google Scholar 

  • Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89(9):897–904. doi:10.1007/s00277-010-0956-7

    Article  PubMed  CAS  Google Scholar 

  • Kim YJ, Kim JH, Park MS, Lee KW, Kim KI, Bang SM, Lee JS, Kim CH (2010) Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy. J Cancer Res Clin Oncol. doi:10.1007/s00432-010-0945-1

  • Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK (2003) Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98(12):2651–2656. doi:10.1002/cncr.11846

    Article  PubMed  CAS  Google Scholar 

  • Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22(21):4302–4311. doi:10.1200/JCO.2004.03.213

    Article  PubMed  CAS  Google Scholar 

  • Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87(5):429–430. doi:10.1007/s00277-008-0447-2

    Article  PubMed  CAS  Google Scholar 

  • Project-TIN-HsLPF (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329(14):987–994. doi:10.1056/NEJM199309303291402

    Article  Google Scholar 

  • Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. doi:10.1182/blood-2006-08-038257

    Article  PubMed  CAS  Google Scholar 

  • Thieblemont C, Coiffier B (2007) Lymphoma in older patients. J Clin Oncol 25(14):1916–1923. doi:10.1200/JCO.2006.10.5957

    Article  PubMed  Google Scholar 

  • Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C, Espinouse D, Coiffier B (2008) Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19(4):774–779. doi:10.1093/annonc/mdm563

    Article  PubMed  CAS  Google Scholar 

  • Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM (1998) CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16(1):27–34

    PubMed  CAS  Google Scholar 

  • Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G (2009) A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115(19):4547–4553. doi:10.1002/cncr.24490

    Article  PubMed  Google Scholar 

  • Winkelmann N, Petersen I, Kiehntopf M, Fricke HJ, Hochhaus A, Wedding U (2010) Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol. doi:10.1007/s00432-010-0933-5

Download references

Acknowledgments

We would like to thank S. Nishinarita at Akiru Municipal Medical Center, M. Mizutani at Mizutani Clinic, I. Nakata at Nakata Clinic, T. Ohshima at Kawagoe Rehabilitation Hospital, A. Yoshizawa at Kanamecho Hospital, K. Ogawa at Yokosuka Municipal Hospital, T. Jinbo at Fujioka General Hospital, N. Honda at Saitama Medical Center, and T. Miyagishima at Kushiro Rosai Hospital for their contribution to this work.

Conflict of interest

We have nothing to disclose other than follows.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katsuhiro Miura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kobayashi, Y., Miura, K., Hojo, A. et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137, 1079–1084 (2011). https://doi.org/10.1007/s00432-010-0973-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0973-x

Keywords